Christoph Stein

Q: What Schools Are Affiliated With Christoph Stein

Christoph Stein is affiliated with the following schools: University of Iowa, Columbia University

Christoph Stein's AcademicInfluence.com Rankings

Christoph Stein

Philosophy

#11729

World Rank

#16206

Historical Rank

Logic

#8534

World Rank

#10694

Historical Rank

philosophy Degrees

Christoph Stein

Biology

#15460

World Rank

#19440

Historical Rank

Genetics

#1811

World Rank

#1926

Historical Rank

Molecular Biology

#2667

World Rank

#2708

Historical Rank

Biochemistry

#2713

World Rank

#2897

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Christoph Stein's Degrees

PhD Biochemistry University of California, Berkeley
Doctorate Medicine Stanford University

Why Is Christoph Stein Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Christoph Stein's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Antisense oligonucleotides as therapeutic agents--is the bullet really magical? (1993) (1251)
Does antisense exist? (1995) (250)
Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein (1997) (250)
Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. (1993) (244)
Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. (1994) (212)
Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacy. (1993) (181)
The experimental use of antisense oligonucleotides: a guide for the perplexed. (2001) (173)
Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells. (1993) (169)
Phosphorothioate antisense oligodeoxynucleotides: questions of specificity. (1996) (147)
Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides. (1997) (131)
Applied antisense oligonucleotide technology (1998) (121)
Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? (1995) (117)
Phosphorothioate oligodeoxynucleotides--anti-sense inhibitors of gene expression? (1991) (104)
Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides. (1996) (92)
Mechanisms of action of taxanes in prostate cancer. (1999) (89)
Oligodeoxynucleotides interact with recombinant CD4 at multiple sites. (1993) (84)
Binding of phosphorothioate oligodeoxynucleotides to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin is P-chirality independent. (1995) (76)
Two problems in antisense biotechnology: in vitro delivery and the design of antisense experiments. (1999) (76)
Phosphorothioate oligodeoxynucleotides bind to the third variable loop domain (v3) of human immunodeficiency virus type 1 gp120. (1993) (74)
Mode of action of 5'-linked cholesteryl phosphorothioate oligodeoxynucleotides in inhibiting syncytia formation and infection by HIV-1 and HIV-2 in vitro. (1991) (68)
Formation of a G-tetrad and higher order structures correlates with biological activity of the RelA (NF-kappaB p65) 'antisense' oligodeoxynucleotide (1997) (66)
Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells. (2001) (63)
How to design an antisense oligodeoxynucleotide experiment: a consensus approach. (1998) (55)
Exploiting the potential of antisense: beyond phosphorothioate oligodeoxynucleotides. (1996) (50)
Sequence-independent inhibition of in vitro vascular smooth muscle cell proliferation, migration, and in vivo neointimal formation by phosphorothioate oligodeoxynucleotides. (1996) (45)
Controversies in the cellular pharmacology of oligodeoxynucleotides. (1997) (44)
Is irrelevant cleavage the price of antisense efficacy? (2000) (38)
Effects of suramin-related and other clinically therapeutic polyanions on protein kinase C activity. (1995) (29)
Antisense strategies to inhibit restenosis. (1999) (28)
Cellular pharmacology and protein binding of phosphoromonothioate and phosphorodithioate oligodeoxynucleotides: a comparative study. (1994) (26)
Cell surface binding and cellular internalization properties of suramin, a novel antineoplastic agent. (1995) (17)
A comparison of guanosine-quartet inhibitory effects versus cytidine homopolymer inhibitory effects on rat neointimal formation. (1998) (16)
Anti-sense oligodeoxynucleotides--promises and pitfalls. (1992) (14)
Polydeoxyguanine motifs in a 12-mer phosphorothioate oligodeoxynucleotide augment binding to the v3 loop of HIV-1 gp120 and potency of HIV-1 inhibition independency of G-tetrad formation. (1996) (14)
Interruption of a transforming growth factor alpha autocrine loop in Caco-2 cells by antisense oligodeoxynucleotides. (1995) (12)
The extracellular domain of CD4 receptor possesses a protein kinase activity (1998) (8)
5'-Cholesteryl-phosphorothioate oligodeoxynucleotides: potent inhibition of methotrexate transport and antagonism of methotrexate toxicity in cells containing the reduced-folate carrier. (1995) (7)
Porous balloon delivery of S-dC28 does not prevent restenosis in the porcine coronary artery model of balloon injury. (1999) (6)
ANTISENSE AND NUCLEIC ACID-BASED THERAPEUTICS: THE NEXT MILLENNIUM (1999) (5)
Effects of S-dC28 on vascular smooth muscle cell adhesion and plasminogen activator production. (1997) (5)
The Genasense 'learning curve' (2007) (3)
Stimulation of calcium influx in HL60 cells by cholesteryl-modified homopolymer oligodeoxynucleotides. (1992) (3)
Interaction of oligonucleotides with cellular receptors. (1991) (3)
Genasense: it ain't over till the fat lady sings. (2007) (3)
Omega-6 polyunsaturated fatty acid-stimulated cellular internalization of phosphorothioate oligodeoxynucleotides: evidence for protein kinase C-zeta dependency. (1999) (2)
Mode of uptake of 5'-cholesteryl-linked phosphodiester oligodeoxynucleotides in HL60 cells. (1991) (2)
Inhibitory nonsequence-specific effects of cytidine homopolymers on in vivo neointimal formation. (1997) (2)
Delivery of Antisense Oligonucleotidesin Vitro: Experimental Points (2000) (1)
Reply to “…and surreal antisense?” (1996) (1)
Controversies in the cellular pharmacology of oligodeoxynucleotides. (1997) (1)
Understanding the Challenges of Nucleic Acid Therapy (1997) (0)
A Special Issue: The Commercial Development of Nucleic Acids (2002) (0)
Antisense Is Here To Stay (1996) (0)
Expanded Prospects for Oligodeoxynucleotide Drugs (2003) (0)
Response to The Genasense 'learning curve' (2007) (0)
The Manuscript Review Process (1993) (0)
Stein Mechanisms of Action Suramin : A Novel Antineoplastic Agent with Multiple Potential Updated Version (2006) (0)
Mechanistic Aspects of the Interaction of Polyanionic Oligodeoxynucleotides with HL60 Cells (1992) (0)
Oligonucleotides: Extrapolating from in vitro to in vivo (1997) (0)
The Pendulum Swings Back (2001) (0)
Yoon Cho-Chung, M.D. (2006) (0)
Five Years of Antisense—Moving Forward Into Our Sixth Year with an Expanded Editorial Focus (1996) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Christoph Stein?

Christoph Stein is affiliated with the following schools:

Christoph Stein's Academic­Influence.com Rankings

Christoph Stein's Degrees

Why Is Christoph Stein Influential?

Christoph Stein's Published Works

Published Works

What Schools Are Affiliated With Christoph Stein?

Christoph Stein's AcademicInfluence.com Rankings